Prof. Maikel Rheinstädter

Prof. Maikel Rheinstädter

Maikel Rheinstädter
Translating Fundamental Biophysics into Next-Generation Therapeutics | Professor at McMaster University | P.Phys. | University Scholar | CEO & Co-Founder of PentaPink Biotech | Co-Founder of Synth-Med Biotechnology

Dr. Maikel Rheinstädter is a professor in the Department of Physics and Astronomy and a member of the Origins Institute at McMaster University. His research group operates at the interface of physics, chemistry, and biology, using a combination of cutting-edge experimental and computational methods to explore fundamental questions about the emergence of complex biological molecules. The lab specializes in developing novel techniques, including acoustic levitation, an automated thermodynamic environment simulator, small-angle X-ray scattering, and molecular dynamics simulations, to study the abiotic synthesis of complex biopolymers. Recently, the lab utilized highly controlled wet-dry cycling to demonstrate divergent polymerization pathways, successfully generating both phosphodiester-linked 'proto-RNA' and novel pyrophosphate-linked ribose polymers from non-activated precursors. These synthesized oligomers are highly resistant to standard enzymatic degradation. This work not only provides key insights into how diverse and stable genetic molecules could have emerged and persisted on early Earth , but it also establishes a sustainable, 'green chemistry' framework for reagent-free biopolymer synthesis. The inherent enzymatic resistance of these unique structures now opens promising new avenues for developing stable nucleic acid therapeutics and scaffolding molecules for biotechnology and medicine.

Dr. Rheinstädter is deeply committed to student mentorship and was recognized for this with a nomination for the President’s Award for Excellence in Graduate Supervision in 2022. He is also a recipient of the Early Researcher Award from the Province of Ontario and has been named a McMaster University Scholar. Bridging the gap between fundamental discovery and real-world application, Dr. Rheinstädter has co-founded two companies, Synth-Med Biotechnology Inc. and PentaPink Biotechnology Inc., to commercialize novel platforms developed in his lab for therapeutic applications. His team is linking foundational scientific inquiry with tangible, innovative outcomes.

Page updated

Google Sites

Report abuse